FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age
Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.
Food Insecurity and the Dangers of Infant Formula Dilution
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
John Browning, MD, highlights the importance of fragrance-free, steroid-free creams in managing atopic dermatitis safely and effectively in children.
Demystifying Infant Formula
Study: Childhood adversity linked to elevated risk of endometriosis
Childhood adversity may raise endometriosis risk, with exposure to violence linked to a twofold increase, a Swedish study of 1.3M women finds.
First infant enrolled in trial of roflumilast cream, 0.05% for atopic dermatitis in infants
The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.
